文献速递妇科

卵巢癌组织学亚型中胚系BRCA1/2致病性变异检出概率的Meta分析

Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
PubMed 文献 · Gynecol Oncol · 2021-10-23

总体合并比例为16.8%(95%CI 14.6-19.2),高级别浆液性癌最高(22.2%),透明细胞癌(3.0%)和黏液性癌(2.5%)最低。结论提示仅限高级别浆液性癌患者进行遗传检测可能不足以识别所有胚系PV携带者。

要点

  • 卵巢癌总体胚系BRCA1/2 PV合并比例为16.8%(95%CI 14.6-19.2)。
  • 高级别浆液性癌胚系BRCA1/2 PV比例最高,为22.2%(95%CI 19.6-25.0)。
  • 透明细胞癌和黏液性癌胚系BRCA1/2 PV比例较低,分别为3.0%和2.5%。

核心结论

  • 胚系BRCA1/2 PV在高级别浆液性卵巢癌患者中最常见,但在其他组织学亚型中也可检出。
  • 仅将遗传易感检测限制于高级别浆液性卵巢癌患者,可能不足以识别所有胚系PV携带者。

研究设计与样本

  • 系统检索PubMed、EMBASE和Web of Science,纳入所有报告各组织学亚型胚系BRCA1/2 PV比例的研究。

主要发现

  • 总体胚系BRCA1/2 PV合并比例为16.8%(95%CI 14.6-19.2)。
  • 高级别浆液性癌为22.2%(95%CI 19.6-25.0),透明细胞癌为3.0%(95%CI 1.6-5.6),黏液性癌为2.5%(95%CI 0.6-9.6)。
  • 基于较小研究子集,体细胞BRCA1/2 PV总合并比例为6.0%(95%CI 5.0-7.3)。
  • 基于9项研究子集,BRIP1、RAD51C、RAD51D、PALB2和ATM胚系PV合计约3%。

临床怎么用

  • 卵巢癌患者遗传检测不应仅局限于高级别浆液性癌,其他组织学亚型也应考虑胚系BRCA1/2检测。

局限性

  • 体细胞BRCA1/2 PV和其他风险基因胚系PV的分析基于较小研究子集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a topic of debate as the prevalence of BRCA1/2 pathogenic variants (PVs) in various histological subtypes is ambiguous. Our primary aim was to investigate the proportion of germline BRCA1/2 PVs per histological subtype. Additionally, we evaluated (i) proportion of somatic BRCA1/2 PVs and (ii) proportion of germline PVs in other ovarian carcinoma risk genes. METHODS: PubMed, EMBASE and Web of Science were systematically searched and we included all studies reporting germline BRCA1/2 PVs per histological subtype. Pooled proportions were calculated using a random-effects meta-analysis model. Subsets of studies were used for secondary analyses. RESULTS: Twenty-eight studies were identified. The overall estimated proportion of germline BRCA1/2 PVs was 16.8% (95% CI 14.6 to 19.2). Presence differed substantially among patients with varying histological subtypes of OC; proportions being highest in high-grade serous (22.2%, 95% CI 19.6 to 25.0) and lowest in clear cell (3.0%, 95% CI 1.6 to 5.6) and mucinous (2.5%, 95% CI 0.6 to 9.6) carcinomas. Somatic BRCA1/2 PVs were present with total estimated proportion of 6.0% (95% CI 5.0 to 7.3), based on a smaller subset of studies. Germline PVs in BRIP1, RAD51C, RAD51D, PALB2, and ATM were present in approximately 3%, based on a subset of nine studies. CONCLUSION: Germline BRCA1/2 PVs are most frequently identified in high-grade serous ovarian carcinoma patients, but are also detected in patients having ovarian carcinomas of other histological subtypes. Limiting genetic predisposition testing to high-grade serous ovarian carcinoma patients will likely be insufficient to identify all patients with a germline PV.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Witjes VM, van Bommel MHD, Ligtenberg MJL, et al. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. Gynecol Oncol. 2021. PMID: 34702566. doi:10.1016/j.ygyno.2021.10.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。